Document:

Confidential Separation Agreement

 Exhibit 10.2 
 Confidential Separation Agreement and General Release and Amendment to 
 Confidentiality
and Non-Disclosure Agreement 
 This Confidential Separation Agreement and General Release (hereafter “Agreement”) is
entered into by and between Orthovita Inc. (hereafter “Orthovita” or “Company”), and Donald L. Scanlan (hereafter “Employee”). As used in this Agreement, “Company” shall include and encompass all of the past,
present, or future parent, affiliated, related and/or subsidiary companies of Orthovita, and its past, present or future directors, shareholders, officers, employees, agents, attorneys and representatives. 
 EMPLOYEE and ORTHOVITA agree to the following terms and conditions in full and final settlement of all matters in any way relating to, or
arising out of, EMPLOYEE’s employment and/or separation from employment with ORTHOVITA. 
 1. Employee’s final day of employment
with the Company will be Friday, June 15, 2007 (“Termination Date”), and Employee hereby resigns as of such date. 
 2.
Subject to Employee’s execution and nonrevocation of this Agreement and in consideration for Employee’s obligations and agreements hereunder, the Company will: 
  

	 	(a)	pay Employee a total of $218,000.00, payable as salary continuation for a period of 12 months, which is equivalent to 12 months of salary continuation at Employee’s current
semi-monthly salary of $9,083.33, minus all taxes and payroll deductions authorized by law. These payments will commence with the Company’s next payroll period following the June 15, 2007, Termination Date, provided that Employee has not
revoked this Agreement prior to the Effective Date (hereinafter defined) of the Agreement. Amounts due under this paragraph 2(a) shall be payable in semi-monthly installments in accordance with Orthovita’s normal payroll cycle;

  

	 	(b)	If EMPLOYEE chooses to continue his group medical and dental benefits under COBRA, ORTHOVITA will pay the COBRA premiums for such medical/dental benefits through the twelve
month period following the Agreement Date; 

  

	 	(c)	Orthovita will provide EMPLOYEE with a payment equal to any reasonable unreimbursed business expenses through June 15, 2007 and any accrued, unused vacation days through the
Agreement Termination Date; and 

  

	 	(d)	Orthovita acknowledges that Employee’s vested status in Orthovita’s matching contributions to Employee’s John Hancock 401(k) Retirement Account is 66% and such vested
percentage will remain intact, but that Employee’s plan account is valued on a daily basis. 

	 	(e)	amend Employee’s non-compete provisions as specified in Section 3 herein below. 

 3. The Company has elected to enforce against Employee his non-compete obligations provided for in
Section 3 (a)—(d) of Employee’s Confidentiality and Non-Disclosure Agreement with the Company dated 1st of October 2004, attached hereto as
Exhibit A, incorporated by reference and made part hereof in its entirety (“CDA”), provided that the Company and Employee agree that this Agreement amends Section 3 and Section 6 of the CDA, and except as explicitly stated
herein, all other provisions in the CDA remain in full force and effect. Further, in the event that Employee breaches the non-compete provisions of the CDA as modified hereby, the Company shall not be obligated to make the payments in Section 2
above. In consideration for the Company’s undertakings as described in Section 2 herein and in accordance with the provisions of this Section 3: 
  

	 	(a)	Employee agrees that upon execution of this Agreement, Employee will return all Company equipment, Company documents and any other Company property including all sales and marketing
literature, in Employee’s possession, custody or control. Such Company property includes any Company equipment and materials in Employee’s home; 

  

	 	(b)	Employee agrees to abide by the following Non-Compete Agreement: 

 1) The “Non-Compete Ending Date” is June 15, 2008. 
 2) “Competitive Areas”
means bone grafting, surgical hemostasis, treatment of vertebral compression fractures, and bioactive structural interbody fusion spine spacer applications. 
 3) Commencing on the Employee’s June 15, 2007, Termination Date of employment with the Company, and continuing through and including the Non-Compete Ending Date of June 15, 2008, (the
“Restriction Period”), Employee will not, without the Company’s express prior written consent, directly or indirectly own, manage, create, operate, sell, market, license, join, control, finance or participate in the
ownership, management, operation, control or financing of, or be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise with, or use or permit his name to be used in connection with, any
person, business, firm, organization, enterprise or entity that develops, designs, manufactures, sells, licenses, markets or provides advice on any technologies, products or products in development in the Competitive Areas (a “Competing
Business”), or sell or license to, or develop for or with a Competing Business any technologies or products in the Competitive Areas. Such products and technologies include, without limitation, those products and technologies which (i) the
Company or any of its 

 
divisions and/or subsidiaries or affiliates has developed, manufactured, sold, licensed or marketed; (ii) have been disclosed to Employee verbally or in
writing during the course of his employment, during any consulting arrangement or as of the Termination Date as being in the process of development, manufacturing, selling, licensing or marketing by the Company, its divisions and/or its affiliates;
and (iii) to Employee’s knowledge, the Company may be in the process of developing, manufacturing, selling, licensing or marketing now or through the Restriction Period. 
 It is recognized by Employee that the business of the Company, its divisions and/or its affiliates and Employee’s connection therewith has been, is
or will be involved in activity throughout the world, and that more limited geographical limitations on this non-competition covenant are therefore not appropriate. 
 The foregoing restrictions shall not be construed to prohibit the ownership by Employee of less than one percent of any class of securities of any corporation which is engaged in any of the foregoing businesses having
a class of securities registered pursuant to the Securities Exchange Act of 1934 (the “Exchange Act”), provided that such ownership represents a passive investment and that neither Employee nor any group of persons including Employee in
any way, either directly or indirectly, manages or exercises control of any such corporation, guarantees any of its financial obligations, otherwise takes any part in its business, other than exercising his rights as a shareholder, or seeks to do
any of the foregoing. 
 4. Employee on behalf of himself and his successors, assigns, heirs and legal representatives
(“Releasors”), hereby voluntarily and knowingly remises, releases, acquits and forever discharges the Company and its representatives, its parent, affiliated and subsidiary corporations, and its and their predecessors, successors,
affiliates, officers, directors, agents, assigns, employees, attorneys, employee benefit plans, employee benefit plan administrators, and employee benefit plan fiduciaries (“Releasees”), from any and all claims, rights, expenses, debts,
demands, costs, contracts, liabilities, obligations, actions, and causes of action of any nature, known or unknown, based upon any fact, circumstance, or event occurring or existing at or prior to Employee’s execution of this Agreement,
including, but not limited to, any and all matters relating to Employee’s employment with the Company or the termination of that employment. This Release specifically includes, but is not limited to, any claims or actions arising out of or
during Employee’s employment with the Company and/or separation of employment, including any claim under the Age Discrimination in Employment Act (“ADEA”), 29 U.S.C. §621 et seq.; Title VII of the Civil Rights Act
of 1964, 42 U.S.C. §2000e et seq.; the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.; the Employee Retirement Income Security Act, 29 U.S.C. §1101 et seq.; 42 U.S.C. §1981
(“Section 1981”); the Pennsylvania Human Relations Act (“PHRA”), 43 P.S. §951 et seq.; the Pennsylvania Wage Payment and Collection Law (“WPCL”), 43 P.S. §260.1 et seq.; the Family
and Medical Leave Act (“FMLA”) and any and all other federal, state or local laws, and any common law claims now or hereafter recognized, as well as all claims for counsel fees and costs. The claims being waived and released include,
without limitation, (a) any and all claims arising from or relating to Employee’s recruitment, hire, employment and termination of employment with the Company; (b) any and all claims of wrongful discharge, emotional distress, 

 
defamation, misrepresentation, fraud, detrimental reliance, breach of contractual obligations, promissory estoppel, negligence, assault and battery,
violation of public policy; (c) any and all claims of unlawful discrimination, harassment and retaliation under applicable federal, state and local laws and regulations; (d) any and all claims of violation of any federal, state, and local
law relating to recruitment, hiring, terms and conditions of employment, and termination of employment; and (e) any and all claims for monetary damages and any other forms of personal relief. This Release is not intended to apply to claims that
cannot be waived by private agreement under applicable law. 
 This release covers any claims Employee may have up to and including the date
of this Agreement, but does not cover claims that arise after the date of this Agreement or those relating to the enforcement of this Agreement, nor will it affect those benefits which are intended to survive Employee’s termination as an
Employee of the Company, such as conversion of group insurance. This Release does not amount to a waiver of any claims for accrued, vested benefits under any employee benefit or pension plan of RELEASEES, subject to the terms and conditions of such
plans and applicable law. 
 Employee acknowledges that this Agreement resolves any and all legal claims that Employee may have against the
Company as of the date of this Agreement, whether known or unknown. 
 5. Employee represents and covenants that Employee will not
communicate or disclose the terms of this Agreement to any persons other than any federal, state or local taxing authorities, Employee’s immediate family, Employee’s attorney or attorneys, and Employee’s accountant or accountants, who
will be instructed by Employee to agree to be bound by the confidential nature of this Agreement. Nothing herein is intended to limit Employee’s ability to disclose or discuss the tax treatment or tax structure of the payments made to Employee
as necessary to address or clarify the appropriate tax treatment of the payments to be made pursuant to Section 2. Employee recognizes and agrees that should it be determined, in a court of law, that Employee violated this section, Employee
shall be required to refund to the Company all monies payable under this Agreement, in addition to any other legal or equitable relief that may be available and awarded to the Company. Nothing in this section, or elsewhere in this Agreement, is
intended to prevent or prohibit Employee from: (i) providing information regarding Employee’s former employment relationship with the Company, as may be required by law or legal process; or (ii) cooperating, participating, or
assisting in any government entity investigation or proceeding. 
 6. Employee understands and agrees that in the course of employment with
the Company, Employee may have acquired confidential information and trade secrets concerning the Company’s business, its future plans and its methods of doing business, including, without limitation, information about its products, services,
product development, customers, technology, financial circumstances, marketing, pricing, costs, compensation and other matters (hereinafter collectively called “Trade Secrets”). 

 
Employee may not reveal or disclose, sell, use, lecture upon, or publish any such Trade Secrets, or authorize anyone else to do so at any time subsequent to
Employee’s employment with the Company. Employee will return all copies and originals of the Company documents, files, lists and other information of a business nature to the Company immediately, (whether or not such includes Trade Secrets) and
any future use of same by Employee is prohibited. 
 7. Employee and the Company mutually agree to refrain from making disparaging, defaming,
derogatory, critical or negative comments regarding each other, the Company’s products, services or officers, directors, employees or former employees of the Company with respect to any past, present or future issues, except if testifying
truthfully in response to a lawfully served subpoena. 
 8. Neither the negotiation, undertaking or signing of this Agreement constitutes or
operates as an acknowledgment or admission that the Company, or any person acting on behalf of the Company, has violated or failed to comply with any provisions of federal or state constitution, statute, law, regulation, municipal ordinance, or
principle of common law. This agreement is made voluntarily to provide an amicable conclusion to Employee’s employment relationship with the Company. 
 9. Employee agrees and understands that the Company does not have, and will not have, any further obligations to provide Employee at any time with any payment, benefit or consideration other than those recited in
Section 2 above. 
 10. Employee hereby agrees and recognizes that Employee’s employment relationship with the Company has been
permanently and irrevocably severed as of the June 15, 2007 Termination Date and that the Company has no obligation, contractual or otherwise, to hire, rehire or re-employ Employee in the future. 
 11. Employee agrees that Employee shall reasonably cooperate with the Company following the Termination Date to assist with legal proceedings with
respect to matters for which Employee was responsible during Employee’s employment with the Company. 
 12. In signing this Agreement,
Employee acknowledges that: 
 (a) Employee has signed this Agreement voluntarily and knowingly in exchange for the consideration described
herein, which Employee acknowledges as adequate and satisfactory. 
 (b) Employee has been advised by the Company to consult with an attorney
before signing this Agreement; 
 (c) Employee has been given a period of at least twenty-one (21) calendar days after the date Employee
received this Agreement, within which to review and consider this Agreement, to discuss it with an attorney of Employee’s own choosing, and to decide whether or not to sign this Agreement. 

 (d) The Employee has consulted with an attorney of his own choosing during this time period. 

(e) In addition, for the period of seven (7) calendar days after the date Employee signs this Agreement (“Revocation Period”), Employee
may revoke it by delivering written notice of revocation to the Company by hand-delivery or by facsimile or e-mail transmission (and retaining proof of successful transmission) using the street, facsimile, or e-mail address to: Patricia A. Twomey,
Vice President, Human Resources, Orthovita Inc., 77 Great Valley Parkway, Malvern, PA, 610.640.9206 (facsimile), PTwomey@Orthovita.com (email); and 
 (f) Neither the Company, nor any of its employees, agents, representatives, or attorneys has made any representations to Employee concerning the terms or effects of this Agreement and other than those contained
herein. 
 13. In the event that any one or more provisions (or portion thereof) of this Agreement is held to be invalid, unlawful, or
unenforceable for any reason, the invalid, unlawful, or unenforceable provision (or portion thereof) shall be construed or modified so as to provide the Company and Affiliates with the maximum protection that is valid, lawful and enforceable,
consistent with the intent of the Company and Employee in entering into this Agreement. If such provision (or portion thereof) cannot be construed or modified so as to be valid, lawful and enforceable, that provision (or portion thereof) shall be
construed as narrowly as possible and shall be severed from the remainder of the Agreement (or provision), and the remainder shall remain in effect and be construed as broadly as possible, as if such invalid, unlawful or unenforceable provision (or
portion thereof) had never been contained in this Agreement. 
 14. This Agreement shall take effect on the first day following the
expiration of the Revocation Period, provided this Agreement has not been revoked by Employee as provided in Section 12 above during such Revocation Period (the “Effective Date”). 
 15. It is agreed and understood that this Agreement contains and comprises the entire understanding of the parties and that there are no additional or
other promises, representations, terms or provisions other than those expressly contained herein. This Agreement shall not be modified except in writing signed by each of the parties. This Agreement supersedes all other prior agreements concerning
the terms of Employee’s employment with the Company, except for the CDA as amended hereby. 
 16. Employee agrees to the jurisdiction of
any court in the Commonwealth of Pennsylvania over all disputes, which may arise involving this Agreement and Employee hereby consents to the assertion of personal jurisdiction over Employee by any such Court in any such action instituted by the
Company pursuant to this section. This Agreement and the obligations of the parties shall be construed, interpreted and enforced in accordance with the laws of Pennsylvania without regard to choice of law provisions. 

 I HAVE READ THIS AGREEMENT. I UNDERSTAND THAT I AM GIVING UP IMPORTANT RIGHTS PER SECTION 4, ABOVE. I
AM AWARE OF MY RIGHT TO CONSULT WITH AN ATTORNEY OF MY OWN CHOOSING DURING THE CONSIDERATION PERIOD, AND THAT THE COMPANY HAS ADVISED ME TO UNDERTAKE SUCH CONSULTATION BEFORE SIGNING THIS AGREEMENT. I SIGN THIS AGREEMENT FREELY AND VOLUNTARILY,
WITHOUT DURESS OR COERCION. 
 IN WITNESS WHEREOF, and intending to be legally bound and under seal, the parties have executed the
foregoing Confidentiality Separation Agreement and General Release and Amendment to Confidentiality and Non-Disclosure Agreement. 
  

			
	Dated: June 21, 2007
		
	By:	 	 /s/ Donald L. Scanlan

	
	ORTHOVITA, INC.
	
	Dated: June 25, 2007
		
	By:	 	 /s/ Antony Koblish

		 	 President & CEO

			
		
	Witness:	 	 /s/ Patricia A. TwomeyCompensation Plan

 Exhibit 10.3 
 ORTHOVITA, INC. 
 2007 OMNIBUS EQUITY COMPENSATION PLAN 
 1. Purpose 
 The purpose of the
Orthovita, Inc. 2007 Omnibus Equity Compensation Plan (the “Plan”) is to provide (i) designated employees of Orthovita, Inc. (the “Company”) and its parent or subsidiaries, (ii) non-employee members of the board of
directors of the Company and (iii) consultants who perform valuable services for the Company or its subsidiaries with the opportunity to receive grants of stock options, stock units, stock awards, stock appreciation rights and other stock-based
awards. The Company believes that the Plan will encourage the participants to contribute materially to the growth of the Company, thereby benefiting the Company’s shareholders, and will align the economic interests of the participants with
those of the shareholders. 
 The Orthovita, Inc. 1997 Equity Compensation Plan (the “1997 Plan”) will be merged with and into this
Plan as of the Effective Date, and no additional grants will be made thereafter under the 1997 Plan. Outstanding grants under the 1997 Plan will continue in effect according to their terms as in effect on the Effective Date (subject to such
amendments as the Committee (as defined below) determines, consistent with the 1997 Plan), and the shares with respect to outstanding grants under the 1997 Plan will be issued or transferred under this Plan. 
 2. Definitions 
 Whenever used
in this Plan, the following terms will have the respective meanings set forth below: 
 (a) “Board” means the
Company’s Board of Directors. 
 (b) “Change of Control” shall be deemed to have occurred if:

 (i) Any “person” (as such term is used in sections 13(d) and 14(d) of the Exchange Act) becomes a “beneficial owner”
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the Company; provided that a Change of Control shall not be
deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the shareholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the
transaction, shares entitling such shareholders to more than 50% of all votes to which all shareholders of the parent corporation would be entitled in the election of directors; 
 (ii) The consummation of (A) a merger or consolidation of the Company with another corporation where the shareholders of the Company, immediately
prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such shareholders to more than 50% of all votes to which all shareholders of the 

 
surviving corporation would be entitled in the election of directors, (B) a sale or other disposition of all or substantially all of the assets of the
Company, or (C) a liquidation or dissolution of the Company; or 
 (iii) Individuals who, as of the Effective Date, constitute the
Board (the “Incumbent Directors”) cease for any reason to constitute at least a majority of the Board; provided, that any person becoming a director subsequent to such date whose election, or nomination for election by the Company’s
shareholders, was approved by a vote of at least a majority of the Incumbent Directors who are directors at the time of such vote shall be, for purposes of this Plan, an Incumbent Director. 
 (c) “Code” means the Internal Revenue Code of 1986, as amended. 
 (d) “Committee” means (i) with respect to Grants to Employees and Consultants, the Board, Compensation Committee of
the Board or another committee appointed by the Board to administer the Plan, (ii) with respect to Grants made to Non-Employee Directors, the Board, and (iii) with respect to Grants that are intended to be “qualified performance-based
compensation” under section 162(m) of the Code, a committee that consists of two or more persons appointed by the Board, all of whom shall be “outside directors” as defined under section 162(m) of the Code and related
Treasury regulations. 
 (e) “Company” means Orthovita, Inc. and any successor corporation. 
 (f) “Company Stock” means the common stock of the Company. 
 (g) “Consultants” means any consultant or advisor who performs services to the Company or any of its subsidiaries.

 (h) “Disability” shall mean a Participant’s becoming disabled within the meaning of the
Company’s long-term disability plan then in effect. 
 (i) “Dividend Equivalent” means an amount
calculated with respect to a Stock Unit, which is determined by multiplying the number of shares of Company Stock subject to the Stock Unit by the per-share cash dividend, or the per-share fair market value (as determined by the Committee) of any
dividend in consideration other than cash, paid by the Company on its Company Stock. If interest is credited on accumulated dividend equivalents, the term “Dividend Equivalent” shall include the accrued interest. 
 (j) “Effective Date” of the Plan means April 12, 2007, subject to approval of the Plan by the shareholders of the
Company. 
 (k) “Employed by, or provide services to, the Employer” shall mean employment as an Employee,
Consultant or Non-Employee Director (so that, for purposes of exercising Options and SARs and satisfying conditions with respect to Stock Units, Stock Awards and Other Stock-Based Awards, a Participant shall not be considered to have terminated
employment until the Participant ceases to be an Employee, Consultant and Non-Employee Director), unless the Board determines otherwise in the Grant Agreement. 

 (l) “Employee” means an employee of the Employer (including an officer
or director who is also an employee), but excluding any person who is classified by the Employer as a “contractor” or “consultant,” no matter how characterized by the Internal Revenue Service, other governmental agency or a
court. Any change of characterization of an individual by the Internal Revenue Service or any court or government agency shall have no effect upon the classification of an individual as an Employee for purposes of this Plan, unless the Committee
determines otherwise. 
 (m) “Employer” means the Company and its subsidiaries. 
 (n) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 (o) “Exercise Price” means the per share price at which shares of Company Stock may be purchased under an Option, as
designated by the Committee. 
 (p) “Fair Market Value” of Company Stock means, unless the Committee
determines otherwise with respect to a particular Grant, (i) if the principal trading market for the Company Stock is a national securities exchange, the last reported sale price of Company Stock on the relevant date or (if there were no trades
on that date) the latest preceding date upon which a sale was reported, (ii) if the Company Stock is not principally traded on such exchange, the mean between the last reported “bid” and “asked” prices of Company Stock on
the relevant date, as reported on the OTC Bulletin Board or (iii) if the Company Stock is not publicly traded or, if publicly traded, is not so reported, the Fair Market Value per share shall be as determined by the Committee. 
 (q) “Grant” means an Option, Stock Unit, Stock Award, SAR or Other Stock-Based Award granted under the Plan. 

(r) “Grant Agreement” means the written instrument that sets forth the terms and conditions of a Grant, including all
amendments thereto. 
 (s) “Incentive Stock Option” means an Option that is intended to meet the requirements
of an incentive stock option under section 422 of the Code. 
 (t) “Non-Employee Director” means a member of
the Board who is not an Employee. 
 (u) “Nonqualified Stock Option” means an Option that is not intended to
be taxed as an incentive stock option under section 422 of the Code. 
 (v) “1933 Act” means the Securities
Act of 1933, as amended. 
 (w) “Option” means an option to purchase shares of Company Stock, as described in
Section 7. 

 (x) “Other Stock-Based Award” means a grant that is based on, measured
by or payable in Company Stock (other than an Option, Stock Unit, Stock Award or SAR), as described in Section 11. 
 (y)
“Participant” means an Employee, Non-Employee Director or Consultant designated by the Committee to participate in the Plan. 
 (z) “Plan” means this Orthovita, Inc. 2007 Omnibus Equity Compensation Plan, as may be amended from time to time. 
 (aa) “SAR” means a stock appreciation right as described in Section 10. 
 (bb) “Stock Award” means an award of Company Stock as described in Section 9. 
 (cc) “Stock Unit” means an award of a phantom unit representing a share of Company Stock, as described in Section 8.

 (dd) “Termination for Cause” shall mean, except to the extent otherwise provided in a Participant’s
Grant Agreement, a finding by the Board, after full consideration of the facts presented on behalf of both the Employer and the Participant, that the Participant has breached his or her employment or service contract with the Employer, or has been
engaged in disloyalty to the Employer, including, without limitation, fraud, embezzlement, theft, commission of a felony or proven dishonesty in the course of his or her employment or service, or has disclosed trade secrets or confidential
information of the Employer to persons not entitled to receive such information. 
 3. Administration 
 (a) Committee. The Plan shall be administered and interpreted by the Committee. Ministerial functions may be performed by an
administrative committee comprised of Company employees appointed by the Committee. 
 (b) Committee Authority. The
Committee shall have the authority to (i) determine the Participants to whom Grants shall be made under the Plan, (ii) determine the type, size and terms and conditions of the Grants to be made to each such Participant,
(iii) determine the time when the Grants will be made and the duration of any applicable exercise or restriction period, including the criteria for exercisability and the acceleration of exercisability, (iv) amend the terms and conditions
of any previously issued Grant, subject to the provisions of Section 19 below, and (v) deal with any other matters arising under the Plan. 
 (c) Committee Determinations. The Committee shall have full power and express discretionary authority to administer and interpret the Plan, to make factual determinations and to adopt or amend such rules,
regulations, agreements and instruments for implementing the Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. The Committee’s interpretations of the Plan and all determinations made by the
Committee pursuant to the powers vested in it hereunder shall be conclusive and binding on all persons having any interest in the Plan or in any awards granted hereunder. All 

 
powers of the Committee shall be executed in its sole discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives
of the Plan and need not be uniform as to similarly situated Participants. 
 (d) Delegation of Authority.
Notwithstanding the foregoing, the Board may delegate to the Chief Executive Officer, in his capacity as a Board member of the Company, the authority to make grants under the Plan, which grants shall not exceed 50,000 option shares to any person per
year, to Employees or Consultants of the Company and its subsidiaries who are not subject to the restrictions of section 16(b) of the Exchange Act and who are not expected to be subject to the limitations of section 162(m) of the Code. The grant of
authority under this subsection 1(d) shall be subject to such conditions and limitations as may be determined by the Board. 
 4.
Grants 
 (a) Grants under the Plan may consist of Options as described in Section 7, Stock Units as described
in Section 8, Stock Awards as described in Section 9, SARs as described in Section 10 and Other Stock-Based Awards as described in Section 11. All Grants shall be subject to such terms and conditions as the Committee deems
appropriate and as are specified in writing by the Committee to the Participant in the Grant Agreement. 
 (b) All Grants
shall be made conditional upon the Participant’s acknowledgement, in writing or by acceptance of the Grant, that all decisions and determinations of the Committee shall be final and binding on the Participant, his or her beneficiaries and any
other person having or claiming an interest under such Grant. Grants under a particular Section of the Plan need not be uniform as among the Participants. 
 5. Shares Subject to the Plan 
 (a) Shares Authorized. The total
aggregate number of shares of Company Stock that may be issued under the Plan is 10,217,770 shares, subject to adjustment as described in subsection (d) below. This aggregate number shall include the shares remaining to be issued under the 1997
Plan (including shares with respect to outstanding grants and shares available for future grants). 
 (b) Source of Shares;
Share Counting. Shares issued under the Plan may be authorized but unissued shares of Company Stock or reacquired shares of Company Stock, including shares purchased by the Company on the open market for purposes of the Plan. If and to the
extent Options or SARs granted under the Plan terminate, expire, or are canceled, forfeited, exchanged or surrendered without having been exercised, and if and to the extent that any Stock Awards, Stock Units, or Other Stock-Based Awards are
forfeited or terminated, or otherwise are not paid in full, the shares reserved for such Grants shall again be available for purposes of the Plan. Shares of Stock surrendered in payment of the Exercise Price of an Option, and shares withheld or
surrendered for payment of taxes, shall not be available for re-issuance under the Plan. If SARs are granted, the full number of 

 
shares subject to the SARs shall be considered issued under the Plan, without regard to the number of shares issued upon exercise of the SARs and without
regard to any cash settlement of the SARs. To the extent that a Grant of Stock Units or other Stock-Based Awards is designated in the Grant Agreement to be paid in cash, and not in shares of Company Stock, such Grants shall not count against the
share limits in subsection (a). 
 (c) Individual Limits. All Grants under the Plan shall be expressed in shares of
Company Stock. The maximum aggregate number of shares of Company Stock with respect to which all Grants may be made under the Plan to any individual during any calendar year shall be 500,000 shares, subject to adjustment as described in subsection
(d) below. The individual limits of this subsection (d) shall apply without regard to whether the Grants are to be paid in Company Stock or cash. All cash payments (other than with respect to Dividend Equivalents) shall equal the Fair
Market Value of the shares of Company Stock to which the cash payments relate. 
 (d) Adjustments. If there is any
change in the number or kind of shares of Company Stock outstanding (i) by reason of a stock dividend, spinoff, recapitalization, stock split, or combination or exchange of shares, (ii) by reason of a merger, reorganization or
consolidation, (iii) by reason of a reclassification or change in par value, or (iv) by reason of any other extraordinary or unusual event affecting the outstanding Company Stock as a class without the Company’s receipt of
consideration, or if the value of outstanding shares of Company Stock is substantially reduced as a result of a spinoff or the Company’s payment of an extraordinary dividend or distribution, the maximum number of shares of Company Stock
available for issuance under the Plan, the maximum number of shares of Company Stock for which any individual may receive Grants in any year, the kind and number of shares covered by outstanding Grants, the kind and number of shares issued and to be
issued under the Plan, and the price per share or the applicable market value of such Grants shall be equitably adjusted by the Committee to reflect any increase or decrease in the number of, or change in the kind or value of, the issued shares of
Company Stock to preclude, to the extent practicable, the enlargement or dilution of rights and benefits under the Plan and such outstanding Grants; provided, however, that any fractional shares resulting from such adjustment shall be eliminated. In
addition, in the event of a Change of Control of the Company, the provisions of Section 16 of the Plan shall apply. Any adjustments to outstanding Grants shall be consistent with section 409A or 424 of the Code, to the extent applicable. Any
adjustments determined by the Committee shall be final, binding and conclusive. 
 6. Eligibility for Participation 

(a) Eligible Persons. All Employees, Non-Employee Directors and Consultants shall be eligible to participate in the Plan.

 (b) Selection of Participants. The Committee shall select Employees, Non-Employee Directors and Consultants to
receive Grants and shall determine the number of shares of Company Stock subject to each Grant. 

 7. Options 
 (a) General Requirements. The Committee may grant Options to Employees, Non-Employee Directors or Consultants upon such terms and
conditions as the Committee deems appropriate under this Section 7. The Committee shall determine the number of shares of Company Stock that will be subject to each Grant of Options to Employees, Non-Employee Directors or Consultants.

 (b) Type of Option, Price and Term. 
 (i) The Committee may grant Incentive Stock Options or Nonqualified Stock Options or any combination of the two, all in accordance with the terms and conditions set forth herein. Incentive Stock Options may be granted
only to Employees of the Company or its parents or subsidiaries, as defined in section 424 of the Code. Nonqualified Stock Options may be granted to Employees, Non-Employee Directors or Consultants. 
 (ii) The Exercise Price of Company Stock subject to an Option shall be determined by the Committee and may be equal to or greater than the Fair Market
Value of a share of Company Stock on the date the Option is granted. However, an Incentive Stock Option may not be granted to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all
classes of stock of the Company or any parent or subsidiary, as defined in section 424 of the Code, unless the Exercise Price per share is not less than 110% of the Fair Market Value of the Company Stock on the date of grant. 
 (iii) The Committee shall determine the term of each Option, which shall not exceed ten years from the date of grant. However, an Incentive Stock Option
that is granted to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any parent or subsidiary, as defined in section 424 of the Code, may not have
a term that exceeds five years from the date of grant. 
 (c) Exercisability of Options. 
 (i) Options shall become exercisable in accordance with such terms and conditions as may be determined by the Committee and specified in the Grant
Agreement. The Committee may grant Options that are subject to achievement of performance goals or other conditions. The Committee may accelerate the exercisability of any or all outstanding Options at any time for any reason. 
 (ii) The Committee may provide in a Grant Agreement that the Participant may elect to exercise part or all of an Option before it otherwise has become
exercisable. Any shares so purchased shall be restricted shares and shall be subject to a repurchase right in favor of the Company during a specified restriction period, with the repurchase price equal to the lesser of (A) the Exercise Price or
(B) the Fair Market Value of such shares at the time of repurchase, or such other restrictions as the Committee deems appropriate. 

 (iii) Options granted to persons who are non-exempt employees under the Fair Labor Standards Act of
1938, as amended, may not be exercisable for at least six months after the date of grant (except that such Options may become exercisable, as determined by the Committee, upon the Participant’s death, disability or retirement, or upon a Change
of Control or other circumstances permitted by applicable regulations). 
 (d) Termination of Employment, Disability or
Death. 
 (i) Except as provided below or in a Grant Agreement, an Option may only be exercised while the Participant is employed by, or
provide services to, the Employer as an Employee, Consultant or member of the Board. In the event that a Participant ceases to be employed by, or provide services to, the Employer for any reason other than a Disability, death, or Termination for
Cause, any Option which is otherwise exercisable by the Participant shall terminate unless exercised within 90 days of the date on which the Participant ceases to be employed by, or provide services to, the Employer (or within such other period of
time as may be specified in the Grant Agreement), but in any event no later than the date of expiration of the Option term. Any of the Participant’s Options that are not otherwise exercisable as of the date on which the Participant ceases to be
employed by, or provide services to, the Employer shall terminate as of such date. 
 (ii) In the event the Participant ceases to be
employed by, or provide services to, the Employer on account of a Termination for Cause, any Option held by the Participant shall terminate as of the date the Participant ceases to be employed by, or provide services to, the Employer. In addition,
the Participant shall automatically forfeit all Option shares for any exercised portion of an Option for which the Employer has not yet delivered the share certificates, upon refund by the Employer of the Exercise Price paid by the Participant for
such shares. 
 (iii) In the event the Participant ceases to be employed by, or provide services to, the Employer because of the
Participant’s Disability, any Option which is otherwise exercisable by the Participant shall terminate unless exercised within one year after the date on which the Participant ceases to be employed by, or provide services to, the Employer (or
within such other period of time as may be specified in the Grant Agreement), but in any event no later than the date of expiration of the Option term. Any of the Participant’s Options which are not otherwise exercisable as of the date on which
the Participant ceases to be employed by, or provide services to, the Employer shall terminate as of such date. 
 (iv) If the Participant
dies while employed by, or provide services to, the Employer or within 90 days after the date on which the Participant ceases to be employed or provide services on account of a termination of employment or service specified in Section 5(d)(i)
above (or within such other period of time as may be specified in the Grant Agreement), any Option that is otherwise exercisable by the Participant shall terminate unless exercised within one year after the date on which the Participant ceases to be
employed by, or provide services to, the Employer (or within such other period of time as may be specified in the Grant Agreement), but in any event no later than the date of expiration of the Option term. Any of the Participant’s Options that
are not otherwise exercisable as of the date on which the Participant ceases to be employed by, or provide services to, the Employer shall terminate as of such date. 

 (e) Exercise of Options. A Participant may exercise an Option that has become
exercisable, in whole or in part, by delivering a notice of exercise to the Company. The Participant shall pay the Exercise Price for the Option (i) in cash, (ii) if permitted by the Committee, by delivering shares of Company Stock owned
by the Participant and having a Fair Market Value on the date of exercise equal to the Exercise Price or by attestation to ownership of shares of Company Stock having an aggregate Fair Market Value on the date of exercise equal to the Exercise
Price, (iii) by payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, (iv) by such other method as the Committee may approve, to the extent permitted by applicable law, or
(v) through any combination of the foregoing. Shares of Company Stock used to exercise an Option shall have been held by the Participant for the requisite period of time to avoid adverse accounting consequences to the Company with respect to
the Option. Payment for the shares pursuant to the Option, and any required withholding taxes, must be received by the time specified by the Committee depending on the type of payment being made, but in all cases prior to the issuance of the Company
Stock. 
 (f) Limits on Incentive Stock Options. Each Incentive Stock Option shall provide that, if the aggregate Fair
Market Value of the stock on the date of the grant with respect to which Incentive Stock Options are exercisable for the first time by a Participant during any calendar year, under the Plan or any other stock option plan of the Company or a parent
or subsidiary, as defined in section 424 of the Code, exceeds $100,000, then the Option, as to the excess, shall be treated as a Nonqualified Stock Option. An Incentive Stock Option shall not be granted to any person who is not an Employee of the
Company or a parent or subsidiary, as defined in section 424 of the Code. 
 8. Stock Units 
 (a) General Requirements. The Committee may grant Stock Units to Employees, Non-Employee Directors or Consultants, upon such terms
and conditions as the Committee deems appropriate under this Section 8. Each Stock Unit shall represent the right of the Participant to receive a share of Company Stock or an amount based on the value of a share of Company Stock. All Stock
Units shall be credited to bookkeeping accounts on the Company’s records for purposes of the Plan. 
 (b) Terms of
Stock Units. The Committee may grant Stock Units that are payable on terms and conditions determined by the Committee, which may include payment based on achievement of performance goals. Stock Units may be paid at the end of a specified vesting
or performance period, or payment may be deferred to a date authorized by the Committee. The Committee shall determine the number of Stock Units to be granted and the requirements applicable to such Stock Units. 
 (c) Payment With Respect to Stock Units. Payment with respect to Stock Units shall be made in cash, in Company Stock, or in a
combination of the two, as determined by the Committee. The Grant Agreement shall specify the maximum number of shares that can be issued under the Stock Units. 

 (d) Requirement of Employment or Service. The Committee shall determine in the
Grant Agreement under what circumstances a Participant may retain Stock Units after termination of the Participant’s employment or service, and the circumstances under which Stock Units may be forfeited. Unless the Committee determines
otherwise, if the Participant ceases to be employed by, or provide service to, the Employer during a specified period, or if other conditions established by the Committee are not met, the Participant’s Stock Units shall be forfeited.

 (e) Dividend Equivalents. The Committee may grant Dividend Equivalents in connection with Stock Units, under such
terms and conditions as the Committee deems appropriate. Dividend Equivalents may be paid to Participants currently or may be deferred. All Dividend Equivalents that are not paid currently shall be credited to bookkeeping accounts on the
Company’s records for purposes of the Plan. Dividend Equivalents may be accrued as a cash obligation, or may be converted to additional Stock Units for the Participant, and deferred Dividend Equivalents may accrue interest, all as determined by
the Committee. The Committee may provide that Dividend Equivalents shall be payable based on the achievement of specific performance goals. Dividend Equivalents may be payable in cash or shares of Company Stock or in a combination of the two, as
determined by the Committee. 
 9. Stock Awards 
 (a) General Requirements. The Committee may issue shares of Company Stock to Employees, Non-Employee Directors or Consultants under
a Stock Award, upon such terms and conditions as the Committee deems appropriate under this Section 9. Shares of Company Stock issued pursuant to Stock Awards may be issued for cash consideration or for no cash consideration, and subject to
restrictions or no restrictions, as determined by the Committee. The Committee may establish conditions under which restrictions on Stock Awards shall lapse over a period of time or according to such other criteria as the Committee deems
appropriate, including restrictions based upon the achievement of specific performance goals. The Committee shall determine the number of shares of Company Stock to be issued pursuant to a Stock Award. 
 (b) Requirement of Employment or Service. The Committee shall determine in the Grant Agreement under what circumstances a
Participant may retain Stock Awards after termination of the Participant’s employment or service, and the circumstances under which Stock Awards may be forfeited. Unless the Committee determines otherwise, if the Participant ceases to be
employed by, or provide services to, the Employer during a period designated in the Grant Agreement, or if other specified conditions are not met, the Stock Award shall terminate as to all shares covered by the Grant as to which the restrictions
have not lapsed, and those shares of Company Stock must be immediately returned to the Company. 

 (c) Restrictions on Transfer. While Stock Awards are subject to restrictions, a
Participant may not sell, assign, transfer, pledge or otherwise dispose of the shares of a Stock Award except upon death as described in Section 15(a). If certificates are issued, each certificate for a share of a Stock Award shall contain a
legend giving appropriate notice of the restrictions in the Grant. The Participant shall be entitled to have the legend removed when all restrictions on such shares have lapsed. The Company may retain possession of any certificates for Stock Awards
until all restrictions on such shares have lapsed. 
 (d) Right to Vote and to Receive Dividends. The Committee shall
determine to what extent, and under what conditions, the Participant shall have the right to vote shares of Stock Awards and to receive any dividends or other distributions paid on such shares during the restriction period. Unless the Committee
determines otherwise, while Stock Awards are subject to any restrictions, the Participant shall have the right to vote shares of Stock Awards and to receive any dividends or other distributions paid on such shares, subject to any restrictions deemed
appropriate by the Committee. The Committee may determine that dividends on Stock Awards shall be withheld while the Stock Awards are subject to restrictions and that the dividends shall be payable only upon the lapse of the restrictions on the
Stock Awards, or on such other terms as the Committee determines. Dividends that are not paid currently shall be credited to bookkeeping accounts on the Company’s records for purposes of the Plan. Accumulated dividends may accrue interest, as
determined by the Committee, and shall be paid in cash, shares of Company Stock, or in such other form as dividends are paid on Company Stock, as determined by the Committee. 
 10. Stock Appreciation Rights 
 (a) General Requirements. The Committee may grant SARs to Employees, Non-Employee Directors or Consultants separately or in tandem with an Option. The Committee shall establish the number of shares, the terms and the base amount of
the SAR at the time the SAR is granted. The base amount of each SAR shall not be less than the Fair Market Value of a share of Company Stock as of the date of grant of the SAR. 
 (b) Tandem SARs. The Committee may grant tandem SARs either at the time the Option is granted or at any time thereafter while the Option remains
outstanding; provided, however, that, in the case of an Incentive Stock Option, SARs may be granted only at the date of the grant of the Incentive Stock Option. In the case of tandem SARs, the number of SARs granted to a Participant that shall be
exercisable during a specified period shall not exceed the number of shares of Company Stock that the Participant may purchase upon the exercise of the related Option during such period. Upon the exercise of an Option, the SARs relating to the
Company Stock covered by such Option shall terminate. Upon the exercise of SARs, the related Option shall terminate to the extent of an equal number of shares of Company Stock. 
 (c) Exercisability. An SAR shall become exercisable in accordance with such terms and conditions as may be specified. The Committee may grant SARs
that are subject to achievement of performance goals or other conditions. The Committee may accelerate the exercisability of any or all outstanding SARs at any time for any reason. The Committee shall determine in the Grant Agreement under what
circumstances and during what periods a Participant may exercise an SAR after termination of employment or service. A 

 
tandem SAR shall be exercisable only while the Option to which it is related is exercisable. SARs may only be exercised while the Participant is employed by,
or providing services to, the Employer or during the applicable period after termination of employment as described in Section 7(d). 
 (d) Grants to Non-Exempt Employees. SARs granted to persons who are non-exempt employees under the Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after the date of grant (except that such
SARs may become exercisable, as determined by the Committee, upon the Participant’s death, Disability or retirement, or upon a Change of Control or other circumstances permitted by applicable regulations). 
 (e) Exercise of SARs. When a Participant exercises SARs, the Participant shall receive in settlement of such SARs an amount equal to the value of
the stock appreciation for the number of SARs exercised. The stock appreciation for an SAR is the amount by which the Fair Market Value of the underlying Company Stock on the date of exercise of the SAR exceeds the base amount of the SAR as
specified in the Grant Agreement. 
 (f) Form of Payment. The Committee shall determine whether the stock appreciation for an SAR
shall be paid in the form of shares of Company Stock, cash or a combination of the two. For purposes of calculating the number of shares of Company Stock to be received, shares of Company Stock shall be valued at their Fair Market Value on the date
of exercise of the SAR. If shares of Company Stock are to be received upon exercise of an SAR, cash shall be delivered in lieu of any fractional share. 
 11. Other Stock-Based Awards 
 The Committee may grant other awards not specified in Sections
7, 8, 9 or 10 above that are based on or measured by Company Stock to Employees, Non-Employee Directors or Consultants, on such terms and conditions as the Committee deems appropriate. Other Stock-Based Awards may be granted subject to achievement
of performance goals or other conditions and may be payable in Company Stock or cash, or in a combination of the two, as determined by the Committee in the Grant Agreement. 
 12. Qualified Performance-Based Compensation 
 (a) Designation as Qualified Performance-Based Compensation. The Committee may determine that Stock Units, Stock Awards or Other Stock-Based Awards granted to an Employee shall be considered “qualified
performance-based compensation” under section 162(m) of the Code, in which case the provisions of this Section 12 shall apply. 
 (b) Performance Goals. When Grants are made under this Section 12, the Committee shall establish in writing (i) the objective performance goals that must be met, (ii) the period during which
performance will be measured, (iii) the maximum amounts that may be paid if the performance goals are met, and (iv) any other conditions that the Committee deems appropriate and consistent with the requirements of section 162(m) of the
Code for “qualified performance-based compensation.” The performance goals shall satisfy the requirements for “qualified performance-based compensation,” including the requirement 

 
that the achievement of the goals be substantially uncertain at the time they are established and that the performance goals be established in such a way
that a third party with knowledge of the relevant facts could determine whether and to what extent the performance goals have been met. The Committee shall not have discretion to increase the amount of compensation that is payable, but may reduce
the amount of compensation that is payable, pursuant to Grants identified by the Committee as “qualified performance-based compensation.” 
 (c) Criteria Used for Objective Performance Goals. The Committee shall use objectively determinable performance goals based on one or more of the following criteria: stock price, earnings per share,
price-earnings multiples, net earnings, operating earnings, revenue, number of days sales outstanding in accounts receivable, productivity, margin, EBITDA (earnings before interest, taxes, depreciation and amortization), net capital employed, return
on assets, shareholder return, return on equity, return on capital employed, growth in assets, unit volume, sales, cash flow, market share, relative performance to a comparison group designated by the Committee, or strategic business criteria
consisting of one or more objectives based on meeting specified revenue goals, market penetration goals, customer growth, geographic business expansion goals, cost targets, budgetary goals, regulatory approvals or clearances of products, regulatory,
clinical trial and product development milestones, or goals relating to acquisitions or divestitures. The performance goals may relate to one or more business units or the performance of the Company and its subsidiaries as a whole, or any
combination of the foregoing. Performance goals need not be uniform as among Participants. 
 (d) Timing of Establishment
of Goals. The Committee shall establish the performance goals in writing either before the beginning of the performance period or during a period ending no later than the earlier of (i) 90 days after the beginning of the performance period
or (ii) the date on which 25% of the performance period has been completed, or such other date as may be required or permitted under applicable regulations under section 162(m) of the Code. 
 (e) Certification of Results. The Committee shall certify the performance results for the performance period specified in the Grant
Agreement after the performance period ends. The Committee shall determine the amount, if any, to be paid pursuant to each Grant based on the achievement of the performance goals and the satisfaction of all other terms of the Grant Agreement.

 (f) Death, Disability or Other Circumstances. The Committee may provide in the Grant Agreement that Grants under
this Section 12 shall be payable, in whole or in part, in the event of the Participant’s death or disability, a Change of Control or under other circumstances consistent with the Treasury regulations and rulings under section 162(m) of the
Code. 
 13. Deferrals 
 The Committee may permit or require a Participant to defer receipt of the payment of cash or the delivery of shares that would otherwise be due to the Participant in connection with any Grant. The Committee shall establish rules and
procedures for any such deferrals, consistent with applicable requirements of section 409A of the Code. 

 14. Withholding of Taxes 
 (a) Required Withholding. All Grants under the Plan shall be subject to applicable federal (including FICA), state and local tax
withholding requirements. The Company may require that the Participant or other person receiving or exercising Grants pay to the Company the amount of any federal, state or local taxes that the Company is required to withhold with respect to such
Grants, or the Company may deduct from other wages paid by the Company the amount of any withholding taxes due with respect to such Grants. 
 (b) Election to Withhold Shares. If the Committee so permits, shares of Company Stock may be withheld to satisfy the Company’s tax withholding obligation with respect to Grants paid in Company Stock, at
the time such Grants become taxable, up to an amount that does not exceed the minimum applicable withholding tax rate for federal (including FICA), state and local tax liabilities. 
 15. Transferability of Grants 
 (a) Restrictions on Transfer. Except as described in subsection (b) below, only the Participant may exercise rights under a Grant during the Participant’s lifetime, and a Participant may not transfer
those rights except by will or by the laws of descent and distribution. When a Participant dies, the personal representative or other person entitled to succeed to the rights of the Participant may exercise such rights. Any such successor must
furnish proof satisfactory to the Company of his or her right to receive the Grant under the Participant’s will or under the applicable laws of descent and distribution. 
 (b) Transfer of Nonqualified Stock Options to or for Family Members. Notwithstanding the foregoing, the Committee may provide, in a
Grant Agreement, that a Participant may transfer Nonqualified Stock Options to family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with applicable securities laws, according to such terms
as the Committee may determine; provided that the Participant receives no consideration for the transfer of a Nonqualified Stock Option and the transferred Nonqualified Stock Option shall continue to be subject to the same terms and conditions as
were applicable to the Nonqualified Stock Option immediately before the transfer. 
 16. Consequences of a Change of Control 

 (a) In the event of a Change of Control, unless the Committee determines otherwise: (i) all outstanding Options and SARs shall be
fully exercisable, and restrictions on outstanding Stock Awards and Stock Units shall lapse, as of the date of the Change of Control or at such other time as the Committee determines, and (ii) the Committee may require that Participants
surrender their outstanding Options and SARs in exchange for one or more payments by the Company, in cash or Company Stock as determined by the Committee, in an amount equal to the amount, if any, by which the then Fair Market Value of the shares of
Company Stock subject to the Participant’s unexercised Options and SARs exceeds the Exercise Price, and on such terms as the Committee determines. 

 (b) In addition, in the event of a Change of Control, the Committee may take any one or more of the
following actions with respect to any or all outstanding Grants, without the consent of any Participant: (i) after giving Participants an opportunity to exercise their outstanding Options and SARs, the Committee may terminate any or all
unexercised Options and SARs at such time as the Committee deems appropriate, (ii) with respect to Participants holding Stock Units and Other Stock-Based Awards, the Committee may determine that such Participants shall receive one or more
payments in settlement of such Stock Units and Other Stock-Based Awards, in such amount and form and on such terms as may be determined by the Committee, or (iii) the Committee may determine that all outstanding Options and SARs that are not
exercised shall be assumed by, or replaced with comparable options or rights by the surviving corporation (or a parent or subsidiary of the surviving corporation), and other outstanding Grants that remain in effect after the Change of Control shall
be converted to similar grants of the surviving corporation (or a parent or subsidiary of the surviving corporation). Such acceleration, surrender, termination, settlement or conversion shall take place as of the date of the Change of Control or
such other date as the Committee may specify. The Committee may provide in a Grant Agreement that a sale or other transaction involving a subsidiary or other business unit of the Company shall be considered a Change of Control for purposes of a
Grant, or the Committee may establish other provisions that shall be applicable in the event of a specified transaction. 
 17.
Requirements for Issuance of Shares 
 No Company Stock shall be issued in connection with any Grant hereunder unless and until all
legal requirements applicable to the issuance of such Company Stock have been complied with to the satisfaction of the Committee. The Committee shall have the right to condition any Grant made to any Participant hereunder on such Participant’s
undertaking in writing to comply with such restrictions on his or her subsequent disposition of such shares of Company Stock as the Committee shall deem necessary or advisable, and certificates representing such shares may be legended to reflect any
such restrictions. Certificates representing shares of Company Stock issued under the Plan will be subject to such stop-transfer orders and other restrictions as may be required by applicable laws, regulations and interpretations, including any
requirement that a legend be placed thereon. No Participant shall have any right as a shareholder with respect to Company Stock covered by a Grant until shares have been issued to the Participant. 
 18. Amendment and Termination of the Plan 
 (a) Amendment. The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not amend the Plan without approval of the shareholders of the Company if such approval is required
in order to comply with the Code or applicable laws, or to comply with applicable stock exchange requirements. No amendment or termination of this Plan shall, without the consent of the Participant, materially impair any rights or obligations under
any Grant previously made to the Participant under the Plan, unless such right has been reserved in the Plan or the Grant Agreement, or except as provided in 

 
Section 19(b) below. Notwithstanding anything in the Plan to the contrary, the Board may amend the Plan in such manner as it deems appropriate in the
event of a change in applicable law or regulations. 
 (b) No Repricing Without Shareholder Approval. Except for
adjustments contemplated by Section 5(d), the Committee may not reprice Options or SARs, nor may the Board amend the Plan to permit repricing of Options or SARs, unless the shareholders of the Company provide prior approval for such repricing.

 (c) Shareholder Approval for “Qualified Performance-Based Compensation.” If Grants are made under
Section 12 above, the Plan must be reapproved by the Company’s shareholders no later than the first shareholders meeting that occurs in the fifth year following the year in which the shareholders previously approved the provisions of
Section 12, if additional Grants are to be made under Section 12 and if required by section 162(m) of the Code or the regulations thereunder. 
 (d) Termination of Plan. The Plan shall terminate on the day immediately preceding the tenth anniversary of its Effective Date, unless the Plan is terminated earlier by the Board or is extended by the Board
with the approval of the shareholders. The termination of the Plan shall not impair the power and authority of the Committee with respect to an outstanding Grant. 
 19. Miscellaneous 
 (a) Effective Date. The Plan shall be effective as
of the Effective Date. 
 (b) Grants in Connection with Corporate Transactions and Otherwise. Nothing contained in this
Plan shall be construed to (i) limit the right of the Committee to make Grants under this Plan in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business or assets of any corporation, firm or
association, including Grants to employees thereof who become Employees, or for other proper corporate purposes, or (ii) limit the right of the Company to grant stock options or make other stock-based awards outside of this Plan. Without
limiting the foregoing, the Committee may make a Grant to an employee of another corporation who becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation involving the
Company in substitution for a grant made by such corporation. The terms and conditions of the Grants may vary from the terms and conditions required by the Plan and from those of the substituted stock incentives, as determined by the Committee

 (c) Compliance with Law. The Plan, the exercise of Options and the obligations of the Company to issue or transfer
shares of Company Stock under Grants shall be subject to all applicable laws and to approvals by any governmental or regulatory agency as may be required. With respect to persons subject to section 16 of the Exchange Act, it is the intent of the
Company that the Plan and all transactions under the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In addition, it is the intent of the Company that Incentive Stock Options comply with the
applicable provisions of 

 
section 422 of the Code, that Grants of “qualified performance-based compensation” comply with the applicable provisions of section 162(m) of the
Code and that, to the extent applicable, Grants comply with the requirements of section 409A of the Code or an exception from such requirements. To the extent that any legal requirement of section 16 of the Exchange Act or section 422, 162(m) or
409A of the Code as set forth in the Plan ceases to be required under section 16 of the Exchange Act or section 422, 162(m) or 409A of the Code, that Plan provision shall cease to apply. The Committee may revoke any Grant if it is contrary to law or
modify a Grant to bring it into compliance with any valid and mandatory government regulation. The Committee may also adopt rules regarding the withholding of taxes on payments to Participants. The Committee may, in its sole discretion, agree to
limit its authority under this Section. 
 (d) Enforceability. The Plan shall be binding upon and enforceable against
the Company and its successors and assigns. 
 (e) Funding of the Plan; Limitation on Rights. This Plan shall be
unfunded. The Company shall not be required to establish any special or separate fund or to make any other segregation of assets to assure the payment of any Grants under this Plan. Nothing contained in the Plan and no action taken pursuant hereto
shall create or be construed to create a fiduciary relationship between the Company and any Participant or any other person. No Participant or any other person shall under any circumstances acquire any property interest in any specific assets of the
Company. To the extent that any person acquires a right to receive payment from the Company hereunder, such right shall be no greater than the right of any unsecured general creditor of the Company. 
 (f) Rights of Participants. Nothing in this Plan shall entitle any Employee, Non-Employee Director or Consultant or other person to
any claim or right to receive a Grant under this Plan. Neither this Plan nor any action taken hereunder shall be construed as giving any individual any rights to be retained by or in the employment or service of the Employer. 
 (g) No Fractional Shares. No fractional shares of Company Stock shall be issued or delivered pursuant to the Plan or any Grant. The
Committee shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated. 
 (h) Employees Subject to Taxation Outside the United States. With respect to Participants who are subject to taxation in countries
other than the United States, the Committee may make Grants on such terms and conditions as the Committee deems appropriate to comply with the laws of the applicable countries, and the Committee may create such procedures, addenda and subplans and
make such modifications as may be necessary or advisable to comply with such laws. 
 (i) Governing Law. The validity,
construction, interpretation and effect of the Plan and Grant Agreements issued under the Plan shall be governed and construed by and determined in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to the conflict
of laws provisions thereof.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]